PR Newswire Clinical TrialsOriginal article
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
Data ReadoutpositiveLeqembiPositive
AI Analysis
Summary
Eisai presented real-world LEADER study data showing Leqembi-treated patients with early Alzheimer's disease had high stability rates, with nearly 83% remaining stable or improving over an average of 17 months of treatment. This positive real-world evidence demonstrates the continued clinical benefit of lecanemab in early AD patients.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Real-world LEADER study data showing 83% of patients remained stable or improved, with >75% stable and nearly 7% improved over average 17 months of treatment
Importance:7/10
Sentiment:
0.80
Alzheimer's diseasereal-world evidencelecanemabAAIC 2026clinical outcomes
Read the original article
Published by PR Newswire Clinical Trials on July 14, 2026 3:41 PM